{"product_id":"foxo4-dri-10mg-vial","title":"FOXO4-DRI 10mg vial","description":"\u003cp data-start=\"337\" data-end=\"699\" class=\"\"\u003e\u003cstrong data-start=\"337\" data-end=\"350\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                             \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN CONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"337\" data-end=\"699\" class=\"\"\u003e\u003cstrong data-start=\"337\" data-end=\"350\"\u003eFOXO4-DRI\u003c\/strong\u003e (FOXO4-D-Retro-Inverso peptide) is a synthetic peptide designed as a selective senolytic agent, initially developed by researchers at Erasmus University Medical Center (Rotterdam, Netherlands). It targets senescent cells—aged cells that no longer divide but persist in the body, driving inflammation, tissue dysfunction, and aging-related diseases.\u003c\/p\u003e\n\u003cp data-start=\"701\" data-end=\"907\" class=\"\"\u003eFOXO4-DRI was introduced by Baar et al. (2017) as a promising tool for selective elimination of senescent cells by disrupting the FOXO4-p53 interaction, a crucial survival mechanism used by senescent cells.\u003c\/p\u003e\n\u003chr data-start=\"909\" data-end=\"912\" class=\"\"\u003e\n\u003ch2 data-start=\"914\" data-end=\"947\" class=\"\"\u003eChemical Properties and Design\u003c\/h2\u003e\n\u003cul data-start=\"949\" data-end=\"1363\"\u003e\n\u003cli data-start=\"949\" data-end=\"995\" class=\"\"\u003e\n\u003cp data-start=\"951\" data-end=\"995\" class=\"\"\u003e\u003cstrong data-start=\"951\" data-end=\"965\"\u003eFull Name:\u003c\/strong\u003e FOXO4-D-Retro-Inverso peptide\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"996\" data-end=\"1155\" class=\"\"\u003e\n\u003cp data-start=\"998\" data-end=\"1155\" class=\"\"\u003e\u003cstrong data-start=\"998\" data-end=\"1012\"\u003eStructure:\u003c\/strong\u003e Synthetic, 26-amino-acid peptide composed entirely of D-amino acids (mirror-image stereoisomers), making it resistant to protease degradation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1156\" data-end=\"1363\" class=\"\"\u003e\n\u003cp data-start=\"1158\" data-end=\"1363\" class=\"\"\u003e\u003cstrong data-start=\"1158\" data-end=\"1182\"\u003eMechanism of Action:\u003c\/strong\u003e Specifically disrupts the interaction between the FOXO4 transcription factor and the tumor-suppressor protein p53 in senescent cells, allowing senescent cells to undergo apoptosis.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"1365\" data-end=\"1368\" class=\"\"\u003e\n\u003ch2 data-start=\"1370\" data-end=\"1403\" class=\"\"\u003eMechanism of Action (Detailed)\u003c\/h2\u003e\n\u003cp data-start=\"1405\" data-end=\"1770\" class=\"\"\u003eSenescent cells resist apoptosis by sequestering the p53 protein in the nucleus via interaction with FOXO4, preventing p53 from initiating programmed cell death. FOXO4-DRI competitively binds FOXO4, liberating p53. This liberation triggers apoptosis specifically in senescent cells while sparing healthy cells, thereby reducing the senescent cell burden in tissues.\u003c\/p\u003e\n\u003cp data-start=\"1772\" data-end=\"2010\" class=\"\"\u003eThis selectivity is a significant advantage over nonspecific senolytics, which might harm healthy cells. Its retro-inverso configuration further enhances stability and bioavailability, making it more suitable for therapeutic applications.\u003c\/p\u003e\n\u003chr data-start=\"2012\" data-end=\"2015\" class=\"\"\u003e\n\u003ch2 data-start=\"2017\" data-end=\"2066\" class=\"\"\u003ePreclinical Research and Therapeutic Potential\u003c\/h2\u003e\n\u003cp data-start=\"2068\" data-end=\"2148\" class=\"\"\u003eFOXO4-DRI has shown remarkable effects across several preclinical rodent models:\u003c\/p\u003e\n\u003ch3 data-start=\"2150\" data-end=\"2194\" class=\"\"\u003e1. Aging and Frailty (Baar et al., 2017)\u003c\/h3\u003e\n\u003cul data-start=\"2195\" data-end=\"2474\"\u003e\n\u003cli data-start=\"2195\" data-end=\"2294\" class=\"\"\u003e\n\u003cp data-start=\"2197\" data-end=\"2294\" class=\"\"\u003e\u003cstrong data-start=\"2197\" data-end=\"2210\"\u003eProtocol:\u003c\/strong\u003e Daily injections (5 mg\/kg) for five consecutive days followed by weekly injections.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2295\" data-end=\"2474\" class=\"\"\u003e\n\u003cp data-start=\"2297\" data-end=\"2311\" class=\"\"\u003e\u003cstrong data-start=\"2297\" data-end=\"2310\"\u003eOutcomes:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"2314\" data-end=\"2474\"\u003e\n\u003cli data-start=\"2314\" data-end=\"2370\" class=\"\"\u003e\n\u003cp data-start=\"2316\" data-end=\"2370\" class=\"\"\u003eImproved physical function (grip strength, endurance).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2373\" data-end=\"2425\" class=\"\"\u003e\n\u003cp data-start=\"2375\" data-end=\"2425\" class=\"\"\u003eReduced senescent cell burden in kidney and liver.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2428\" data-end=\"2474\" class=\"\"\u003e\n\u003cp data-start=\"2430\" data-end=\"2474\" class=\"\"\u003eImproved coat quality and skin rejuvenation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2476\" data-end=\"2534\" class=\"\"\u003e2. Chemotherapy-induced Senescence (Doxorubicin Model)\u003c\/h3\u003e\n\u003cul data-start=\"2535\" data-end=\"2702\"\u003e\n\u003cli data-start=\"2535\" data-end=\"2573\" class=\"\"\u003e\n\u003cp data-start=\"2537\" data-end=\"2573\" class=\"\"\u003e\u003cstrong data-start=\"2537\" data-end=\"2550\"\u003eProtocol:\u003c\/strong\u003e 5 mg\/kg, every 3 days.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2574\" data-end=\"2702\" class=\"\"\u003e\n\u003cp data-start=\"2576\" data-end=\"2590\" class=\"\"\u003e\u003cstrong data-start=\"2576\" data-end=\"2589\"\u003eOutcomes:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"2593\" data-end=\"2702\"\u003e\n\u003cli data-start=\"2593\" data-end=\"2643\" class=\"\"\u003e\n\u003cp data-start=\"2595\" data-end=\"2643\" class=\"\"\u003eRestoration of hematopoietic stem cell function.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2646\" data-end=\"2702\" class=\"\"\u003e\n\u003cp data-start=\"2648\" data-end=\"2702\" class=\"\"\u003eReduced chemotherapy-induced frailty and organ damage.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2704\" data-end=\"2746\" class=\"\"\u003e3. Pulmonary and Organ Fibrosis Models\u003c\/h3\u003e\n\u003cul data-start=\"2747\" data-end=\"2949\"\u003e\n\u003cli data-start=\"2747\" data-end=\"2810\" class=\"\"\u003e\n\u003cp data-start=\"2749\" data-end=\"2810\" class=\"\"\u003e\u003cstrong data-start=\"2749\" data-end=\"2762\"\u003eProtocol:\u003c\/strong\u003e Subcutaneous injections (3 mg\/kg every 2 days).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2811\" data-end=\"2949\" class=\"\"\u003e\n\u003cp data-start=\"2813\" data-end=\"2827\" class=\"\"\u003e\u003cstrong data-start=\"2813\" data-end=\"2826\"\u003eOutcomes:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"2830\" data-end=\"2949\"\u003e\n\u003cli data-start=\"2830\" data-end=\"2893\" class=\"\"\u003e\n\u003cp data-start=\"2832\" data-end=\"2893\" class=\"\"\u003eReduction in lung fibrosis and improved respiratory function.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2896\" data-end=\"2949\" class=\"\"\u003e\n\u003cp data-start=\"2898\" data-end=\"2949\" class=\"\"\u003eDecreased collagen deposition and fibrotic markers.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"2951\" data-end=\"3017\" class=\"\"\u003e4. Cancer (Experimental Models: Triple-negative Breast Cancer)\u003c\/h3\u003e\n\u003cul data-start=\"3018\" data-end=\"3217\"\u003e\n\u003cli data-start=\"3018\" data-end=\"3217\" class=\"\"\u003e\n\u003cp data-start=\"3020\" data-end=\"3217\" class=\"\"\u003eFOXO4-DRI derivatives (e.g., CL04177) showed potent effects on reducing tumor growth, metastases, and recurrence in mouse xenograft models by targeting chemotherapy-resistant senescent tumor cells.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"3219\" data-end=\"3222\" class=\"\"\u003e\n\u003ch2 data-start=\"3224\" data-end=\"3261\" class=\"\"\u003ePotential Therapeutic Applications\u003c\/h2\u003e\n\u003cul data-start=\"3263\" data-end=\"3711\"\u003e\n\u003cli data-start=\"3263\" data-end=\"3334\" class=\"\"\u003e\n\u003cp data-start=\"3265\" data-end=\"3334\" class=\"\"\u003e\u003cstrong data-start=\"3265\" data-end=\"3299\"\u003eSenescence-associated diseases\u003c\/strong\u003e (generalized anti-aging, frailty).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3335\" data-end=\"3413\" class=\"\"\u003e\n\u003cp data-start=\"3337\" data-end=\"3413\" class=\"\"\u003e\u003cstrong data-start=\"3337\" data-end=\"3358\"\u003eFibrotic diseases\u003c\/strong\u003e (pulmonary fibrosis, liver cirrhosis, renal fibrosis).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3414\" data-end=\"3498\" class=\"\"\u003e\n\u003cp data-start=\"3416\" data-end=\"3498\" class=\"\"\u003e\u003cstrong data-start=\"3416\" data-end=\"3445\"\u003eChemotherapy side effects\u003c\/strong\u003e (reducing chemotherapy-induced cellular senescence).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3499\" data-end=\"3604\" class=\"\"\u003e\n\u003cp data-start=\"3501\" data-end=\"3604\" class=\"\"\u003e\u003cstrong data-start=\"3501\" data-end=\"3519\"\u003eCancer therapy\u003c\/strong\u003e (targeting senescent tumor cells, particularly chemotherapy-resistant cancer cells).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3605\" data-end=\"3711\" class=\"\"\u003e\n\u003cp data-start=\"3607\" data-end=\"3711\" class=\"\"\u003e\u003cstrong data-start=\"3607\" data-end=\"3642\"\u003eHormonal and reproductive aging\u003c\/strong\u003e (restoring testicular function and steroidogenesis in aging models).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"3713\" data-end=\"3716\" class=\"\"\u003e\n\u003ch2 data-start=\"3718\" data-end=\"3762\" class=\"\"\u003eExperimental Dosage (Preclinical Context)\u003c\/h2\u003e\n\u003cp data-start=\"3764\" data-end=\"3860\" class=\"\"\u003eThe following dosages are extrapolated from rodent studies and represent experimental protocols:\u003c\/p\u003e\n\u003cul data-start=\"3862\" data-end=\"4147\"\u003e\n\u003cli data-start=\"3862\" data-end=\"3987\" class=\"\"\u003e\n\u003cp data-start=\"3864\" data-end=\"3894\" class=\"\"\u003e\u003cstrong data-start=\"3864\" data-end=\"3893\"\u003eIntraperitoneal (common):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"3897\" data-end=\"3987\"\u003e\n\u003cli data-start=\"3897\" data-end=\"3937\" class=\"\"\u003e\n\u003cp data-start=\"3899\" data-end=\"3937\" class=\"\"\u003eInitial Phase: 5 mg\/kg daily × 5 days.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3940\" data-end=\"3987\" class=\"\"\u003e\n\u003cp data-start=\"3942\" data-end=\"3987\" class=\"\"\u003eMaintenance Phase: 5 mg\/kg weekly thereafter.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3988\" data-end=\"4059\" class=\"\"\u003e\n\u003cp data-start=\"3990\" data-end=\"4059\" class=\"\"\u003e\u003cstrong data-start=\"3990\" data-end=\"4007\"\u003eSubcutaneous:\u003c\/strong\u003e 3 mg\/kg every 48 hours (common in fibrosis models).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4060\" data-end=\"4147\" class=\"\"\u003e\n\u003cp data-start=\"4062\" data-end=\"4147\" class=\"\"\u003e\u003cstrong data-start=\"4062\" data-end=\"4100\"\u003eIntravenous (derivative peptides):\u003c\/strong\u003e ~1-2 mg\/kg weekly (experimental oncology use).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cblockquote data-start=\"4149\" data-end=\"4243\"\u003e\n\u003cp data-start=\"4151\" data-end=\"4243\" class=\"\"\u003e\u003cstrong data-start=\"4151\" data-end=\"4160\"\u003eNote:\u003c\/strong\u003e Human-equivalent doses are yet undetermined and require rigorous clinical testing.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"4245\" data-end=\"4248\" class=\"\"\u003e\n\u003ch2 data-start=\"4250\" data-end=\"4287\" class=\"\"\u003eSafety Profile and Potential Risks\u003c\/h2\u003e\n\u003ch3 data-start=\"4289\" data-end=\"4319\" class=\"\"\u003ePotential Safety Concerns:\u003c\/h3\u003e\n\u003cul data-start=\"4320\" data-end=\"4836\"\u003e\n\u003cli data-start=\"4320\" data-end=\"4444\" class=\"\"\u003e\n\u003cp data-start=\"4322\" data-end=\"4444\" class=\"\"\u003e\u003cstrong data-start=\"4322\" data-end=\"4356\"\u003eLoss of beneficial senescence:\u003c\/strong\u003e Not all senescent cells are detrimental (some facilitate wound healing, tissue repair).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4445\" data-end=\"4573\" class=\"\"\u003e\n\u003cp data-start=\"4447\" data-end=\"4573\" class=\"\"\u003e\u003cstrong data-start=\"4447\" data-end=\"4474\"\u003ep53 pathway modulation:\u003c\/strong\u003e Long-term manipulation of p53 requires careful consideration due to its role in tumor suppression.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4574\" data-end=\"4699\" class=\"\"\u003e\n\u003cp data-start=\"4576\" data-end=\"4699\" class=\"\"\u003e\u003cstrong data-start=\"4576\" data-end=\"4595\"\u003eImmunogenicity:\u003c\/strong\u003e While D-amino acids reduce immunogenicity, repeated administrations may still trigger immune responses.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4700\" data-end=\"4836\" class=\"\"\u003e\n\u003cp data-start=\"4702\" data-end=\"4836\" class=\"\"\u003e\u003cstrong data-start=\"4702\" data-end=\"4730\"\u003eUnknown Long-Term Risks:\u003c\/strong\u003e No extensive long-term studies to evaluate chronic use, potential carcinogenic risk, or systemic effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"4838\" data-end=\"4881\" class=\"\"\u003eReported Side Effects (Rodent studies):\u003c\/h3\u003e\n\u003cul data-start=\"4882\" data-end=\"5050\"\u003e\n\u003cli data-start=\"4882\" data-end=\"4938\" class=\"\"\u003e\n\u003cp data-start=\"4884\" data-end=\"4938\" class=\"\"\u003eMild, transient weight loss or lethargy at initiation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4939\" data-end=\"5050\" class=\"\"\u003e\n\u003cp data-start=\"4941\" data-end=\"5050\" class=\"\"\u003eNo major toxicity noted short-term, but chronic administration and long-term safety remain largely unstudied.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5052\" data-end=\"5055\" class=\"\"\u003e\n\u003ch2 data-start=\"5057\" data-end=\"5104\" class=\"\"\u003eRegulatory Status and Developmental Pipeline\u003c\/h2\u003e\n\u003cp data-start=\"5106\" data-end=\"5123\" class=\"\"\u003eAs of April 2025:\u003c\/p\u003e\n\u003cul data-start=\"5124\" data-end=\"5703\"\u003e\n\u003cli data-start=\"5124\" data-end=\"5188\" class=\"\"\u003e\n\u003cp data-start=\"5126\" data-end=\"5188\" class=\"\"\u003eFOXO4-DRI remains an \u003cstrong data-start=\"5147\" data-end=\"5187\"\u003eexperimental, research-only compound\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5189\" data-end=\"5427\" class=\"\"\u003e\n\u003cp data-start=\"5191\" data-end=\"5427\" class=\"\"\u003e\u003cstrong data-start=\"5191\" data-end=\"5223\"\u003eCleara Biotech (Netherlands)\u003c\/strong\u003e, the company formed by the original FOXO4-DRI inventors, is currently optimizing second-generation derivatives (e.g., CL04177, CL04183) for improved pharmacokinetics, selectivity, and therapeutic window.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5428\" data-end=\"5594\" class=\"\"\u003e\n\u003cp data-start=\"5430\" data-end=\"5594\" class=\"\"\u003eNo formal clinical trials (Phase I or later) have been registered or initiated, though Cleara indicates plans for Phase I oncology trials within the next 18 months.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5595\" data-end=\"5703\" class=\"\"\u003e\n\u003cp data-start=\"5597\" data-end=\"5703\" class=\"\"\u003eCurrent status: IND-enabling studies are underway for derivatives targeting specific oncology indications.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5705\" data-end=\"5708\" class=\"\"\u003e\n\u003ch2 data-start=\"5710\" data-end=\"5746\" class=\"\"\u003eKey Limitations and Research Gaps\u003c\/h2\u003e\n\u003cul data-start=\"5748\" data-end=\"6208\"\u003e\n\u003cli data-start=\"5748\" data-end=\"5856\" class=\"\"\u003e\n\u003cp data-start=\"5750\" data-end=\"5856\" class=\"\"\u003e\u003cstrong data-start=\"5750\" data-end=\"5782\"\u003eLack of human clinical data:\u003c\/strong\u003e All available efficacy and safety data derive solely from animal studies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5857\" data-end=\"5980\" class=\"\"\u003e\n\u003cp data-start=\"5859\" data-end=\"5980\" class=\"\"\u003e\u003cstrong data-start=\"5859\" data-end=\"5887\"\u003eOptimal dosing strategy:\u003c\/strong\u003e Frequency, duration, and appropriate administration routes in humans remain uncharacterized.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5981\" data-end=\"6094\" class=\"\"\u003e\n\u003cp data-start=\"5983\" data-end=\"6094\" class=\"\"\u003e\u003cstrong data-start=\"5983\" data-end=\"6004\"\u003eLong-term safety:\u003c\/strong\u003e No chronic toxicity, immunogenicity, or cancer-risk assessment in long-term human trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6095\" data-end=\"6208\" class=\"\"\u003e\n\u003cp data-start=\"6097\" data-end=\"6208\" class=\"\"\u003e\u003cstrong data-start=\"6097\" data-end=\"6123\"\u003eBiomarker development:\u003c\/strong\u003e Needed to reliably distinguish harmful vs. beneficial senescent cell subpopulations.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"6210\" data-end=\"6213\" class=\"\"\u003e\n\u003ch2 data-start=\"6215\" data-end=\"6235\" class=\"\"\u003eFuture Directions\u003c\/h2\u003e\n\u003cul data-start=\"6237\" data-end=\"6650\"\u003e\n\u003cli data-start=\"6237\" data-end=\"6342\" class=\"\"\u003e\n\u003cp data-start=\"6239\" data-end=\"6342\" class=\"\"\u003e\u003cstrong data-start=\"6239\" data-end=\"6265\"\u003eFirst-in-human trials:\u003c\/strong\u003e Critical for determining safety, pharmacokinetics, and therapeutic efficacy.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6343\" data-end=\"6524\" class=\"\"\u003e\n\u003cp data-start=\"6345\" data-end=\"6524\" class=\"\"\u003e\u003cstrong data-start=\"6345\" data-end=\"6385\"\u003eDevelopment of improved derivatives:\u003c\/strong\u003e Cleara Biotech’s next-generation peptides promise greater selectivity and bioavailability, potentially addressing earlier safety concerns.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6525\" data-end=\"6650\" class=\"\"\u003e\n\u003cp data-start=\"6527\" data-end=\"6650\" class=\"\"\u003e\u003cstrong data-start=\"6527\" data-end=\"6553\"\u003eCombination therapies:\u003c\/strong\u003e Potential synergy with other senolytics, chemotherapeutics, or regenerative medicine approaches.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"6652\" data-end=\"6655\" class=\"\"\u003e\n\u003ch2 data-start=\"6657\" data-end=\"6690\" class=\"\"\u003eConclusion and Current Outlook\u003c\/h2\u003e\n\u003cp data-start=\"6692\" data-end=\"7238\" class=\"\"\u003eFOXO4-DRI represents a pioneering concept in the rapidly growing field of senolytics, targeting a fundamental mechanism underlying cellular senescence. Preclinical research has provided compelling evidence of its potential to treat age-related diseases, fibrosis, cancer recurrence, and chemotherapy-induced damage. However, \u003cstrong data-start=\"7017\" data-end=\"7069\"\u003eno human clinical trials have yet been conducted\u003c\/strong\u003e, and significant safety and efficacy questions remain. As such, FOXO4-DRI currently remains an exciting, yet strictly experimental peptide awaiting clinical validation.\u003c\/p\u003e\n\u003chr data-start=\"7240\" data-end=\"7243\" class=\"\"\u003e\n\u003ch2 data-start=\"7245\" data-end=\"7272\" class=\"\"\u003eReferences \u003c\/h2\u003e\n\u003cul data-start=\"7274\" data-end=\"7633\"\u003e\n\u003cli data-start=\"7274\" data-end=\"7392\" class=\"\"\u003e\n\u003cp data-start=\"7276\" data-end=\"7392\" class=\"\"\u003eBaar MP et al. (2017). \"Targeted apoptosis of senescent cells restores tissue homeostasis.\" \u003cem data-start=\"7368\" data-end=\"7374\"\u003eCell\u003c\/em\u003e, 169(1), 132-147.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7393\" data-end=\"7508\" class=\"\"\u003e\n\u003cp data-start=\"7395\" data-end=\"7508\" class=\"\"\u003eCleara Biotech official announcements (2022-2025): Senolytic pipeline updates and derivatives (CL04177, CL04183).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7509\" data-end=\"7633\" class=\"\"\u003e\n\u003cp data-start=\"7511\" data-end=\"7633\" class=\"\"\u003eCroker JA et al. (2024). \"Therapy-induced senescence: FOXO4-DRI as a targeted senolytic approach.\" \u003cem data-start=\"7610\" data-end=\"7633\"\u003eTrends Pharmacol Science.\u003c\/em\u003e\u003cem data-start=\"7610\" data-end=\"7633\"\u003e\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong data-start=\"7640\" data-end=\"7655\"\u003eDisclaimer:\u003c\/strong\u003e\u003cbr data-start=\"7655\" data-end=\"7658\"\u003e\u003cspan\u003eThis review is provided solely for educational purposes. FOXO4-DRI remains an experimental compound without regulatory approval for human use. Always consult qualified healthcare providers before considering any experimental treatments or interventions.\u003c\/span\u003e\u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684861505874,"sku":"10","price":50.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/FOX04-DRI_10mg.png?v=1770834911","url":"https:\/\/sciencepeptideslab.com\/products\/foxo4-dri-10mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}